Glioblastoma Multiforme Treatment Market to Rise at a Healthy CAGR of 11.4% During the Forecast Period of 2014 to 2022

Glioblastoma multiforme (GBM) is the most frequent and lethal primary brain tumor in adults. The current treatment modalities available in the market are surgical resection followed by chemotherapy and radiotherapy, that unable to increase the overall survival of patient. The main reason behind inability of these treatments are frequent recurrence, invasiveness of GBM and resistance of glioma stem cells to conventional treatments. Therefore, novel alternative treatment strategies are desperately needed and pipeline of GBM already involves a mix of biological, immunotherapy, small molecules and other types of therapeutics. Recent advancements in molecular biology and gene technology have provided attractive novel treatment possibilities for the patients diagnosed with GBM.

This research report on the glioblastoma treatment market explains various advancements in this market and analyzes the global glioblastoma treatment market based on drugs (commercially available and pipeline) and geographic regions. The report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments dominating the market and expected to grow at the highest growth rate during the forecast period are included in the report in a precise manner.

Geographically, the glioblastoma treatment market has been categorized into North America, Europe, Asia-Pacific and Rest of the World. The market size and forecast for each of these regions have been provided for the period from 2012 to 2022 along with CAGR (%) for the forecast period from 2014 to 2022.

Request for the Sample Report @

A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of major players in the glioblastoma treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include AbbVie, Inc., Activartis Biotech GmbH, Bristol-Myers Squibb Co., Merrimack Pharmaceuticals, Inc., F. Hoffman La Roche, and Tau Therapeutics.

Leave a Reply

Your email address will not be published. Required fields are marked *